🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with figures suggesting over 82 million infections annually. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are increasingly worried about the rise in drug-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This approval marks a significant shift in the treatment of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

Based on data detailed in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the typical regimen, which uses an injection and a pill. The trial involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to make available and distribute the drug in a wide range of developing nations.

Clinicians on the front lines have expressed positive views. Access to a easy-to-administer therapy such as this is seen as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.